Pharmaceutical

Eton acquires US rights to neonatal diabetes treatment from AMMTeK

Eton has acquired the rights in the US to Amglidia for neonatal diabetes mellitus, from French biotechnology company AMMTeK.

Nov 27, 2024 - 06:00
Eton acquires US rights to neonatal diabetes treatment from AMMTeK
Eton has acquired the rights in the US to Amglidia for neonatal diabetes mellitus, from French biotechnology company AMMTeK.
Read the original article

Tags:

Previous Article

NHS rolls out monoclonal antibody treatment for rare bone disease  

Next Article

Roche’s tiragolumab flops in another Phase III lung cancer trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA oncology head wants advisory panels to keep voting on new drugs

STAT+: FDA oncology head wants advisory panels to keep ...

Jun 6, 2023

Herpes Labialis (Oral Herpes) drugs in development, 2023

Nov 30, 2023

Opinion: Listen: What we take for granted after 30 years of Prozac

Opinion: Listen: What we take for granted after 30 year...

Nov 29, 2023